News provided by University of Colorado Anschutz Jul 29, 2026, 00:00 ET A study from the University of Colorado Anschutz found that the popular diabetes and weight loss drug reduced heavy drinking and alcohol-related harm in adults with Alcohol Use Disorder AURORA, Colo., July 29, 2026 /PRNewswire/ -- A clinical trial led by researchers at CU Anschutz has found that oral semaglutide, a medication widely used for diabetes and weight loss, reduces heavy drinking in adults with Alcohol Use Disorder (AUD)
The people who could benefit most from these medications are often those least able to afford them, perpetuating a cycle in which geography, income, and health outcomes remain tightly intertwined
Alternating makes more sense when you tolerate each medication for limited periods, when cost and availability force periodic changes, or when a clinician designs a specific cycling protocol for your unique situation
Leucine is especially recognized for its powerful anabolic properties, directly stimulating muscle growth and recovery
[PMID: 36200118] PubMed record related to this compound for laboratory literature review
Long-term safety data for semaglutide comes from diabetes trials lasting approximately 2 years and the SELECT cardiovascular outcomes trial with median follow-up of about 3.3 years
